McKesson Corporation ($MCK) Stock Forecast: Up 13.6% Today

What is McKesson Corporation?

McKesson (MCK) is a leading healthcare company specializing in pharmaceutical distribution and services. The company has been experiencing strong financial performance and investor confidence, recently reaching an all-time high stock price.

Why is McKesson Corporation going up?

MCK stock is up 13.6% on Feb 5, 2026 17:37

• Strong fiscal third-quarter results were reported by McKesson, with a focus on oncology, biopharma services, and pharmaceutical distribution, leading to a bullish market movement.
• The company's strategic shift towards its core drug distribution and services, as well as the potential IPO of its medical surgical business, has garnered positive investor sentiment and contributed to the stock's surge.
• Despite a Zacks Rank of #3 (Hold) and cautious outlook, the overall market response to McKesson's robust operational strategies and exceeding analyst expectations in Q3 fiscal 2026 results has been overwhelmingly positive, driving the stock to new heights.

MCK Price Chart

MCK Technical Analysis

MCK News

McKesson’s Strong Quarter Highlights Shift Toward Post Separation Focus

McKesson (NYSE:MCK) reported strong fiscal third-quarter results, driven by momentum in oncology, biopharma services, and pharmaceutical distribution. The company is progressing with the planned IPO of its medical surgical business by the second half of 2027, which will enable McKesson to focus on its core drug distribution and services. This strategic shift and solid financial performance, including raised full-year EPS guidance, reflect the company's evolving business model and potential for future growth in specialty pharmaceuticals.

https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/mckessons-strong-quarter-highlights-shift-toward-post-separa

McKesson (MCK) Is Considered a Good Investment by Brokers: Is That True?

McKesson (MCK) currently holds an average brokerage recommendation (ABR) of 1.47, indicating a Strong Buy to Buy rating from 17 firms. However, the article cautions against relying solely on ABRs due to inherent positive bias from brokerage firms, suggesting that the Zacks Rank, which is based on earnings estimate revisions, is a more reliable indicator for stock performance. McKesson currently has a Zacks Rank #3 (Hold), leading to a more cautious outlook despite the favorable ABR.

https://finviz.com/news/301558/mckesson-mck-is-considered-a-good-investment-by-brokers-is-that-true

McKesson stock hits all-time high at 896.26 USD

McKesson Corporation's stock has reached an all-time high of 896.26 USD, reflecting a 55.28% surge over the past year due to strong performance and investor confidence. The company also reported exceeding analyst expectations in its Q3 fiscal 2026 financial results with an adjusted EPS of $9.34 and revenue of $106.16 billion, though aftermarket trading saw a stock decline. These achievements highlight McKesson's robust operational strategies and potential for future growth within the evolving healthcare sector.

https://www.investing.com/news/company-news/mckesson-stock-hits-alltime-high-at-89626-usd-93CH-4488148

McKesson Corporation (NYSE:MCK) Q3 2026 earnings call transcript

This article is an earnings call transcript for McKesson Corporation's Q3 2026 results. It contains the detailed discussions and financial reporting from the company's conference call with investors and analysts.

https://www.msn.com/en-us/money/companies/mckesson-corporation-nyse-mck-q3-2026-earnings-call-transcript/ar-AA1VJIXu?ocid=finance-verthp-feeds

Cardinal Health (NYSE:CAH) Exceeds Q4 CY2025 Expectations

Cardinal Health (NYSE:CAH) announced Q4 CY2025 results that surpassed market expectations, with an 18.8% year-on-year revenue increase to $65.63 billion and non-GAAP profit exceeding analyst estimates by 11.2%. The company also raised its full-year Adjusted EPS guidance to $10.25 at the midpoint. This strong performance was driven by double-digit segment profit growth across all operating segments, indicating a solid financial quarter for the healthcare distributor.

https://finviz.com/news/301086/cardinal-health-nyse-cah-exceeds-q4-cy2025-expectations

Trending Today

O'Reilly Automotive Inc. ($ORLY) Stock Forecast: Down 5.8% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Down 5.1% Today

Wix.com Ltd. ($WIX) Stock Forecast: Down 5.2% Today

Ralph Lauren Corporation ($RL) Stock Forecast: Down 5.0% Today

Verisk Analytics Inc. ($VRSK) Stock Forecast: Down 5.0% Today

KKR & Co. Inc. Class A ($KKR) Stock Forecast: Down 5.2% Today

Bitcoin ($BTC) Crypto Forecast: Down 11.0% Today

S&P Global Inc. ($SPGI) Stock Forecast: Down 4.0% Today

Eli Lilly and Company ($LLY) Stock Forecast: Down 5.8% Today

Huntington Ingalls Industries Inc. ($HII) Stock Forecast: Down 12.1% Today

McKesson Corporation Price History

02.00.2026 - MCK Stock was up 1.4%

• Accurate Wealth Management LLC and Allspring Global Investments Holdings LLC notably increased their holdings in McKesson Corporation, signaling a rise in confidence in the company's future.
• McKesson's Q3 earnings exceeded expectations, with a 10.2% year-over-year revenue growth, surpassing EPS projections. This strong financial performance likely contributed to the uptick in the stock.
• Analysts uphold a "Moderate Buy" consensus rating on McKesson, with a target price of $892.86, reflecting positivity about the company's growth potential.
• The steady performance of McKesson shares relative to the NYSE Composite Index highlights the company's consistent and reliable position in the market, making it an attractive investment option.

05.01.2026 - MCK Stock was up 13.6%

• Strong fiscal third-quarter results were reported by McKesson, with a focus on oncology, biopharma services, and pharmaceutical distribution, leading to a bullish market movement.
• The company's strategic shift towards its core drug distribution and services, as well as the potential IPO of its medical surgical business, has garnered positive investor sentiment and contributed to the stock's surge.
• Despite a Zacks Rank of #3 (Hold) and cautious outlook, the overall market response to McKesson's robust operational strategies and exceeding analyst expectations in Q3 fiscal 2026 results has been overwhelmingly positive, driving the stock to new heights.

23.08.2025 - MCK Stock was up 5.1%

• McKesson's stock price rose by +1.19% higher than the market, indicating strong investor interest.
• This bullish movement could be attributed to positive earnings reports, potential new partnerships, or overall optimism in the healthcare sector.
• Investors may be reacting positively to McKesson's strategic initiatives or market developments, driving the stock price higher.
• The outperformance of McKesson compared to the market suggests that investors have confidence in the company's future prospects, leading to the bullish movement.

26.08.2025 - MCK Stock was up 5.4%

• The stock of McKesson had a strong bullish movement today, outperforming the broader market.
• Information points to the long-term growth potential of investing in McKesson, showcasing how a $1000 investment made years ago would have significantly appreciated.
• Despite a recent dip in stock price, McKesson has historically shown resilience and strong performance, with an average annual return of 14.69% over the past 20 years.
• The positive movement in McKesson's stock price today could be attributed to the company's consistent growth trajectory and investor confidence in its long-term prospects, despite short-term fluctuations.

03.05.2025 - MCK Stock was down 1.2%

• The recent downtrend in McKesson's stock could be due to profit-taking by investors following an extended period of growth.
• Market movements may reflect wider economic uncertainties or specific challenges within the healthcare sector affecting the company's stock value.
• Investor decisions may be influenced by short-term market changes rather than the company's overall long-term success.
• Monitoring McKesson's response to the market decline and potential factors that could reverse this trend is important going forward.

08.00.2026 - MCK Stock was down 2.2%

• The bearish movement in MCK's stock today could be attributed to the insider selling activity by Thomas Rodgers, the Chief Strategy & Business Development Officer. This could have raised concerns among investors about the company's future prospects.
• The fresh analyst commentary on McKesson's valuation, while highlighting its strong performance and earnings potential, may not have been enough to offset the impact of the insider selling news.
• The overall market sentiment towards healthcare supply chain companies like McKesson might have been affected by the potential risks mentioned, such as drug pricing pressures and vertical integration by manufacturers, leading to a bearish trend in the stock price.
• Despite the positive outlook on injectable GLP-1 drugs driving demand for related companies like West Pharmaceutical Services, the focus on McKesson's insider selling and valuation concerns could have overshadowed any potential industry growth prospects, contributing to the bearish movement in the stock.

05.00.2026 - MCK Stock was down 1.5%

• An increase in Motco's stake in McKesson Corporation might have initially boosted investor confidence, but various other factors could have shifted the overall market sentiment.
• The lowering of Cencora's price target by B of A Securities may have affected the pharmaceutical sector, including McKesson Corporation, leading to a bearish market trend.
• Despite positive news about the growth of the Palliative Care Market and McKesson's strong performance, the stock faced downward pressure possibly due to broader market conditions or specific internal concerns.
• Varied opinions on the stock performance and stability of Cencora Inc. in comparison to McKesson Corporation could have influenced investors to reallocate their funds, impacting McKesson's stock price negatively.

07.07.2025 - MCK Stock was down 5.2%

• McKesson (MCK) exceeded Q1 earnings and revenue projections, displaying robust financial results.
• Despite increased prescription volume driven by GLP-1 demand, lower margins might have influenced profitability.
• The company has demonstrated consistent growth and a strong average annual return, outperforming the market in the last 5 years.
• Today, McKesson (MCK) faced a bearish trend, declining more than the broader market, potentially linked to profit-taking following recent positive developments and concerns about margin pressures impacting profitability.

07.07.2025 - MCK Stock was down 7.5%

• Q1 earnings surpassed expectations and the FY26 EPS outlook was raised, but McKesson's stock faced a downward trend.
• Investor concerns were influenced by a decreasing gross margin and uncertainties regarding the company's spin-off plans, contributing to the decline in stock value.
• Despite strong prescription volume growth driven by GLP-1 demand, it may not have fully countered the impact of reduced margins on overall profitability.
• The market reaction, including a sell-off, seemed to indicate that investors were anticipating even more robust performance from McKesson despite the positive earnings outcomes.

06.00.2026 - MCK Stock was up 1.8%

• An institutional investor, Robeco Institutional Asset Management B.V., notably increased its holdings in McKesson Corporation, indicating strong confidence in the company's future.
• McKesson's Q3 earnings surpassed expectations, with earnings per share exceeding forecasts and a 10.2% revenue growth from the previous year, potentially boosting investor confidence.
• The company's emphasis on specialty and automation services, coupled with strategic expansions like venturing into the biopharma and provider ecosystem, played a key role in driving its positive earnings trajectory.
• Positive sentiments from analysts, institutional investors, and the company's financial performance likely contributed to the recent bullish movement in McKesson's stock.

05.01.2026 - MCK Stock was up 13.6%

• MCK witnessed a strong uptrend in trading today.
• This positive movement could be linked to the company's Q3 2026 results, where although revenue slightly missed expectations, the adjusted EPS exceeded forecasts. This robust performance and the raised annual profit guidance likely bolstered investor confidence.
• The favorable atmosphere in the healthcare domain, exemplified by Cardinal Health (CAH) surpassing estimates and revising its profit outlook due to heightened demand for specialized medications, may have further influenced MCK's upward trajectory.
• Investors seem positive about McKesson's strategic positioning in healthcare, particularly its emphasis on specialty pharmaceuticals and potential growth prospects within the market.

31.06.2025 - MCK Stock was down 2.9%

• Today's decline in McKesson's stock may be due to investor profit-taking following a recent period of optimism.
• Despite anticipated earnings growth and favorable analyst recommendations, various market dynamics and external influences might have contributed to the stock's downturn.
• Market volatility or broader economic uncertainties could have overshadowed the company's short-term growth outlook, prompting the bearish shift.
• It is advisable for investors to monitor developments within the healthcare sector and overall market conditions that could affect McKesson's stock performance in the immediate future.